Telix signed a definitive agreement to acquire QSAM Biosciences for its lead asset Samarium-153-DOTMP (153Sm-DOTMP) a product developed for the treatment of metastatic bone cancer. The transaction details remain undisclosed
153Sm-DOTMP is a kit-based bone-seeking targeted radiopharmaceutical product that utilizes a chelating agent to deliver a formulation of Samarium-153 radioisotope
In pre-clinical & early clinical trials 153Sm-DOTMP has depicted significant safety, efficacy & future commercial utility with the potential to deliver significant improvements on prior bone-seeking agents in the treatment and management of late-stage metastatic disease. Earlier, 153Sm-DOTMP the US FDA’s ODD & RPDD for the treatment of osteosarcoma
Ref: Telix Pharmaceuticals | Image: Telix Pharmaceuticals
Related News:- Telix Presented P-III Results from TLX250-CDx for Kidney Cancer Imaging Study at the ASCO GU 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
